Immunotherapy plus endostatin and chemo for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage III non-small cell lung cancer that cannot be removed by surgery.
- This is your first treatment for this lung cancer – you cannot have had chemotherapy, radiation, or other drugs for it before.
- Your cancer should not have certain gene changes (like EGFR, ALK, ROS1, RET, HER2, or MET). If you have non-squamous type, these gene tests must be done.
- You must be between 18 and 75 years old, in good enough health to get chemotherapy (ECOG score 0-1), and have at least one tumor that can be measured.
- Your kidney, liver, and blood cell counts must be within certain limits, and you must not have had serious bleeding or blood clots recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests whether adding an immunotherapy drug (Serplulimab) to chemotherapy before surgery can help people with advanced stage III non-small cell lung cancer that cannot be removed. It aims to shrink the tumor and improve outcomes.
Hear when a new Unresectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.